Heather Wilson Robles Min

Cancer is the most common cause of death in dogs over the age of 2 years in the US

Up to 50% of all dogs over the age of 10 will develop cancer in their lifetimes.

With approximately 77 million pet dogs in the United States, there are an estimated 6 million pet dogs diagnosed with cancer each year.

Dog Scene 2 1

Earlier detection can save lives

It can also improve the quality of life of the dog and its owner.

Yet, as of today, there are few single assay cancer blood tests on the veterinary market. Currently, dogs suspected of having cancer are required to undergo a variety of diagnostic tests that may be expensive, time consuming and/or painful for the animal.

We hope to change this with the introduction of the Nu.Q® Vet Cancer Screening Test – now available from the GI Lab at Texas A&M University.

The Nu.Q® Vet Cancer Screening Test is a simple, low-cost, easy to use ELISA based screening blood test which will help streamline the diagnostic process for “older or at risk” dogs.

The benefit for the Veterinarian, the owner and the dog is a streamlined diagnostic process: simpler, quicker and less painful diagnosis. We hope to aid earlier detection of cancer and the saving of lives.

Veterinarians can click here to order today from the GI Lab at Texas A& M University or call 979-709-2348 with any questions.

Low Res Vcs Data Thumbnail
Product Information - for Veterinarians & Pet Owners
Dolan Et Al
Characterizing circulating nucleosomes in the plasma of dogs with lymphoma
Hemangio Paper
Characterizing circulating nucleosomes in the plasma of dogs with hemangiosarcoma
Product Brochure Fc
Nu.Q® Vet Product Brochure - Veterinarians
Pet Owner Fc
Nu.Q® Vet Pet Owner Leaflet
How To Interpret Results
How to process a sample and interpret results
Front Cover
A Look to the Future of Cancer Diagnostics - Expert Led Report
Vet Laptop Hr
Evaluation of nucleosome concentrations in healthy dogs and dogs with cancer

Intellectual Property

Covers human and veterinary applications.

Believed to be the only company working on ELISA measurement or epigenetically modified circulating nucleosomes.

As of September 30, 2021:

  • 30
    Patent families
  • 12
    Patents granted in the U.S.
  • 14
    Patents granted in Europe
  • 56
    Additional patents granted worldwide
  • 82
    Patents pending